Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-25-060802
Filing Date
2025-03-24
Accepted
2025-03-24 06:13:44
Documents
13
Period of Report
2024-12-30
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d928346d8ka.htm   iXBRL 8-K/A 25560
  Complete submission text file 0001193125-25-060802.txt   152567

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA grtx-20241230.xsd EX-101.SCH 2511
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE grtx-20241230_lab.xml EX-101.LAB 18663
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grtx-20241230_pre.xml EX-101.PRE 11672
16 EXTRACTED XBRL INSTANCE DOCUMENT d928346d8ka_htm.xml XML 5419
Mailing Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

EIN.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39114 | Film No.: 25762154
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)